KCNB2

Across TCGA pan-cancer cohorts, KCNB2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated KCNB2 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher KCNB2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KCNB2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

READ, BLCA, and PAAD are the cancer types where KCNB2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	OS	Median	II,III,IV	0.234	0.848	<.001	32	view →
BLCA	OS	Median	IV	0.079	0.611	<.001	15	view →
PAAD	OS	Median	All	0.112	0.640	.004	12	view →
UCEC	DFS	Median	All	0.844	0.627	.007	12	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
SKCM	DFS	Median	III,IV	0.431	0.685	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

KCNB2–READ (OS)

Open the READ breakdown →